Brokerages Set Capricor Therapeutics Inc (NASDAQ:CAPR) Target Price at $35.50

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) have been given a consensus recommendation of "Buy" by the six research firms that are presently covering the company, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $35.50.

CAPR has been the subject of several research analyst reports. Wall Street Zen cut shares of Capricor Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Roth Capital initiated coverage on shares of Capricor Therapeutics in a research note on Tuesday, May 20th. They set a "buy" rating and a $31.00 target price for the company. Cantor Fitzgerald reiterated an "overweight" rating and set a $30.00 target price on shares of Capricor Therapeutics in a research note on Wednesday, May 14th. Finally, HC Wainwright restated a "buy" rating and issued a $77.00 price objective on shares of Capricor Therapeutics in a research note on Monday, March 17th.

Capricor Therapeutics Trading Down 5.3%

NASDAQ:CAPR traded down $0.56 during trading hours on Friday, hitting $10.09. 1,313,951 shares of the company traded hands, compared to its average volume of 1,736,516. The stock has a market capitalization of $460.88 million, a price-to-earnings ratio of -9.52 and a beta of 0.85. Capricor Therapeutics has a twelve month low of $3.52 and a twelve month high of $23.40. The firm has a 50-day moving average of $10.28 and a 200 day moving average of $13.22.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.20). The company had revenue of $2.73 million for the quarter, compared to analyst estimates of $3.16 million. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. During the same quarter in the previous year, the company earned ($0.31) earnings per share. Equities research analysts predict that Capricor Therapeutics will post -1.21 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Capricor Therapeutics

Hedge funds have recently made changes to their positions in the company. Summit Investment Advisors Inc. increased its position in shares of Capricor Therapeutics by 54.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company's stock worth $53,000 after purchasing an additional 1,345 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Capricor Therapeutics by 172.8% in the 4th quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company's stock valued at $64,000 after purchasing an additional 2,947 shares during the last quarter. Virtus ETF Advisers LLC bought a new position in shares of Capricor Therapeutics in the 4th quarter valued at about $68,000. AlphaQuest LLC bought a new position in shares of Capricor Therapeutics in the 4th quarter valued at about $78,000. Finally, New York State Common Retirement Fund boosted its stake in shares of Capricor Therapeutics by 625.0% in the 4th quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company's stock valued at $80,000 after purchasing an additional 5,000 shares during the last quarter. Institutional investors and hedge funds own 21.68% of the company's stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.